The relationship between thiopurine methyltransferase activity and genotype in blasts from patients with acute leukemia

Blood

Volumn 92, Issue 8, 1998, Pages 2856-2862

  Coulthard, Sally A ^a   Howell, Christopher ^a   Robson, Jill ^a   Hall, Andrew G ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

THIOPURINE METHYLTRANSFERASE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; BLAST CELL; CHILD; CLINICAL ARTICLE; FEMALE; GENE ACTIVITY; GENE MUTATION; GENOTYPE; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL;

EID: 0032532599     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v92.8.2856     Document Type: Article

References (39)

1. Chessells JM, Bailey C, Richards SM: Intensification of treatment and survival in all children with lymphoblastic leukaemia: Results of UK Medical Research Council trial UKALLX. Lancet 345:143, 1995
2. Schorin MA, Blattner S, Gelber RD, Tarbell NJ, Donnelly M, Dalton V, Cohen HJ, Sallan SE: Treatment of childhood acute lymphoblastic leukemia: Results of Dana-Farber Cancer Institute/Children's Hospital Acute Lymphoblastic Leukemia Consortium Protocol 85-01. J Clin Oncol 12:740, 1994
3. Waber DP, Tarbell NJ, Fairclough D, Atmore K, Castro R, Isquith P, Lussier F, Romero I, Carpenter PJ, Schiller M, Sallan SE: Cognitive sequelae of treatment in childhood acute lymphoblastic leukemia: Cranial radiation requires an accomplice. J Clin Oncol 13:2490, 1995
4. Smibert E, Anderson V, Godber T, Ekert H: Risk factors for intellectual and educational sequelae of cranial irradiation in childhood acute lymphoblastic leukaemia. Br J Cancer 73:825, 1996
5. Didcock E, Davies HA, Didi M, Stuart ALO, Wales JKH, Shalet SM: Pubertal growth in young adult survivors of childhood leukemia. J Clin Oncol 13:2503, 1995
6. Hawkins MM, Wilson LM, Stovall MA, Marsden HB, Potok MHN, Kingston JE, Chessells JM: Epipodophyllotoxins, alkylating agents, and radiation and risk of secondary leukaemia after childhood cancer. Br Med J 304:951, 1992
7. Pinkel D: Selecting treatment for children with acute lymphoblastic leukemia. J Clin Oncol 14:4, 1996
8. Evans WE, Relling MV: Clinical pharmacokinetics-pharmacodynamics of anticancer drugs. Clin Pharmacokinet 16:327, 1989
9. Galpin AJ, Evans WE: Therapeutic drug monitoring in cancer management, Clin Chem 39:2419, 1993
10. 6-methylthioguanine. Biochemistry 36:2501, 1997
11. Swann PF, Waters TR, Moulton DC, Xu YZ, Zheng QG, Edwards M, Mace R: Role of postreplicative DNA mismatch repair in the cytotoxic action of thioguanine. Science 273:1109, 1996
12. Guerciolini R, Szumlanski C, Weinshilboum RM: Human liver xanthine oxidase: Nature and extent of individual variation. Clin Pharmacol Ther 50:663, 1991
13. Weinshilboum RM, Sladek SL: Mercaptopurine pharmacogenetics: Monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am J Hum Genet 32:651, 1980
14. Otterness D, Szumlanski C, Lennard L, Klemetsdal B, Aarbakke J, Park-Hah JO, Iven H, Schmiegelow K, Branum E, O'Brien J, Weinshilboum R: Human thiopurine methyltransferase pharmacogenetics: Gene sequence polymorphisms. Clin Pharmacol Ther 62:60, 1997
15. Evans WE, Horner M, Chu YQ, Kalwinsky D, Roberts WM: Altered mercaptopurine metabolism, toxic effects, and dosage requirement in a thiopurine methyltransferase-deficient child with acute lymphocytic leukemia. J Pediatr 119:985, 1991
16. Escousse A, Mousson C, Santona L, Zanetta G, Mounier J, Tanter Y, Duperray F, Rifle G, Chevet D: Azathioprine-induced pancytopenia in homozygous thiopurine methyltransferase-deficient renal transplant recipients: A family study. Transplant Proc 27:1739, 1995
17. Lennard L, Gibson BES, Nicole T, Lilleyman JS: Congenital thiopurine methyltransferase deficiency and 6-mercaptopurine toxicity during treatment for acute lymphoblastic leukaemia. Arch Dis Child 69:577, 1993
18. Lennard L, Van Loon JA, Weinshilboum RM: Pharmacogenetics of acute azothioprine toxicity: Relationship to thiopurine methyltransferase genetic polymorphism. Clin Pharmacol Ther 46:149, 1989
19. Lennard L, Lilleyman JS, Van Loon J, Weinshilboum RM: Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukaemia. Lancet 336:225, 1990
20. Lennard L, Welch JC, Lilleyman JS: Thiopurine drugs in the treatment of childhood leukaemia: The influence of inherited thiopurine methyltransferase activity on drug metabolism and cytotoxicity. Br J Clin Pharmacol 44:455, 1997
21. Lilleyman JS, Lennard L: Mercaptopurine metabolism and risk of relapse in childhood lymphoblastic leukaemia. Lancet 343:1188, 1994
22. Honchel R, Aksoy IA, Szumlanski C, Wood TC, Otterness DM, Wieben ED, Weinshilboum RM: Human thiopurine methyltransferase: Molecular cloning and expression of T84 colon carcinoma cell cDNA. Mol Pharmacol 43:878, 1993
23. Szumlanski C, Otterness D, Her C, Lee D, Brandriff B, Kelsell D, Spurr N, Lennard L, Wieben E, Weinshilboum R: Thiopurine methyltransferase pharmacogenetics: Human gene cloning and characterization of a common polymorphism. DNA Cell Biol 15:17, 1996
24. Yates CR, Krynetski EY, Locnnechen T, Fessing MY, Tai HL, Pui CH, Relling MV, Evans WE: Molecular diagnosis of thiopurine S-methyltransferase deficiency: Genetic basis for azathioprine and mercaptopurine intolerance. Ann Intern Med 126:608, 1997
25. Tai HL, Krynetski EY, Schuetz EG, Yanishevski Y, Evans WE: Enhanced proteolysis of thiopurine 5-methyltransferase (TPMT) encoded by mutant alleles in humans (TPMT*3A, TPMT*2): Mechanisms for the genetic polymorphism of TPMT activity. Proc Natl Acad Sci USA94:6444, 1997
26. McLeod HL, Relling MV, Liu Q, Pui C-H, Evans WE: Polymorphic thiopurine methyltransferase in erythrocytes is indicative of activity in leukemic blasts from children with acute lymphoblastic leukemia. Blood 85:1897, 1995
27. Weinshilboum RM, Raymond FA, Pazmino PA: Human erythrocyte thiopurine methyltransferase: Radiochemical microassay and biochemical properties. Clin Chim Acta 85:323, 1978
28. Hon YY, Evans WE: Making TDM work to optimize cancer chemotherapy: A multidisciplinary team approach. Clin Chem 44:388, 1998
29. Evans WE, Relling MV, Rodman JH, Crom WR, Boyett JM, Pui CH: Conventional compared with individualized chemotherapy for childhood acute lymphoblastic leukemia. N Engl J Med 338:499, 1998
30. Roberts WM, Estrov Z, Kitchingman GR, Zipf TF: The clinical significance of residual disease in childhood acute lymphoblastic leukemia as detected by polymerase chain reaction amplification of antigen-receptor gene sequences. Leuk Lymphoma 20:181, 1996
31. Working party on leukaemia in childhood: Improvement in treatment for children with acute lymphoblastic leukaemia; the Medical Research Council UKALL trials 1972-84. Lancet 1:408, 1986
32. Mahoney DH, Camitta BM, Leventhal BG, Shuster JJ, Civin CJ, Ganick DJ, Lauer SJ, Steuber CP, Kamen BA: Repetitive low dose oral methotrexate and intravenous mercaptopurine treatment for patients with lower risk B-lineage acute lymphoblastic leukemia, A Pediatric Oncology Group pilot study. Cancer 75:2623, 1995
33. Veerman AJP, Hahlen K, Kamps WA, Van Leeuwen EF, De Vaan GAM, Solbu G, Suciu S, Van Wering ER, Van Der Does-Van Den Berg A: High cure rate with a moderately intensive treatment regimen in non-high-risk childhood acute lymphoblastic leukemia. Results of protocol ALL VI from the Dutch Childhood Leukemia Study Group. J Clin Oncol 14:911, 1996
34. Welch JC, Lilleyman JS: 6-mercaptopurine dose escalation and its effect on drug tolerance in childhood lymphoblastic leukaemia. Cancer Chemother Pharmacol 38:113, 1996
35. Lilleyman JS, Lennard L: Non-compliance with oral chemotherapy in childhood leukaemia - An overlooked and costly cause of late relapse. Br Med J 1313:1219, 1996
36. Zimm S, Collins JM, Riccardi R, O'Neill D, Narang PK, Chabner B, Poplack DG: Variable bioavailability of oral 6-mercaptopurine: Is maintenance chemotherapy in acute lymphoblastic leukaemia being optimally delivered? N Engl J Med 308:1005, 1983
37. Weinshilboum RM, Sladek SL: Mercaptopurine pharmacogenetics: Monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am J Hum Genet 32:651, 1980
38. Tai HL, Krynetski EY, Yates CR, Loennechen T, Fessing MY, Krynetskaia NF, Evans WE: Thiopurine S-methyltransferase deficiency: Two nucleotide transitions define the most prevalent mutant allele associated with loss of catalytic activity in Caucasians. Am J Hum Genet 58:694, 1996
39. Evans WE, Relling MV: Mercaptopurine vs thioguanine for the treatment of acute lymphoblastic leukemia. Leuk Res 18:811, 1994